Personality
7
Open
6
Cons
5
Extr
5
Agre
5
Neur
Wockhardt
Healthcare · Mid Cap
Distressed / Turnaround · Founder-Centric
About
Dr. Murtaza Khorakiwala is the Managing Director of Wockhardt, a Mid Cap company in the Healthcare sector with a market cap of ₹21K Cr. A Visionary leader with 27 years of experience, he is known for intuition-driven decision-making and organic builder strategy. Maintains a high-risk research trajectory, heavily committing resources to antibiotic development and global clinical R&D pipelines.
FAQ
What is Dr. Murtaza Khorakiwala's leadership style?
Dr. Murtaza Khorakiwala is classified as a Visionary leader. He is intuition-driven in decision-making, with a category creator motivation and seasonal-burst pace of execution.
What is Dr. Murtaza Khorakiwala's educational background?
Dr. Murtaza Khorakiwala holds a Medicine (MBBS) from GS Medical College and a MBA from University of Illinois.
Who is the CEO of Wockhardt?
Dr. Murtaza Khorakiwala is the Managing Director of Wockhardt. He has been with the company for 27 years and in the current role for 16 years.
Leadership DNA
ArchetypeVisionary
MotivationCategory Creator
CrisisRestructurer
DecisionIntuition-Driven
GrowthOrganic Builder
PeopleRelationship Led
InnovationFast-Follower
PaceSeasonal-Burst
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerLearning Ground
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Maintains a high-risk research trajectory, heavily committing resources to antibiotic development and global clinical R&D pipelines.”
⚡ Crisis●●●●○
He led a significant multi-year restructuring of Wockhardt by selling off the nutrition business and exiting non-core markets to deleverage the balance sheet and focus on R&D.
🎯 Motivation●●●●○
His leadership is defined by a deep focus on 'new drug discovery' and developing proprietary intellectual property in the anti-infectives space rather than just generic manufacturing.
👥 People●●●○○
As a promoter-MD, he maintains a culture of deep organizational loyalty and personal oversight of key scientific and leadership talent within the family-founded enterprise.
📈 Growth●●●●○
Wockhardt's recent growth has been driven by internal R&D investments and building proprietary anti-infective clinical pipelines rather than large-scale M&A.
💡 Innovation●●●●○
The company focuses on complex generics and biosimilars, leveraging established clinical pathways rather than pioneering entirely new drug categories.
🏃 Pace●●●○○
Operational tempo is dictated by the cyclical nature of debt restructuring, regulatory approvals, and turnaround milestones rather than consistent growth.
🌱 Purpose●●●○○
The company emphasizes its legacy in affordable healthcare and antibiotic research, though its recent strategy is heavily constrained by financial restructuring needs.
🏷️ Brand●●●●○
The company maintains a reputation for deep technical capabilities in specialized areas like sterile injectables and antibiotic research.
🤝 Customer●●●●○
The company primarily operates through global partnerships, contract manufacturing, and institutional supply chains rather than direct-to-consumer retail brands.
💼 Employer●●●○○
It is historically recognized as a training ground for pharmaceutical professionals in India, despite recent challenges with high leadership turnover.
📋 Mandate
Mandatory stabilization of the balance sheet and operational efficiency to restore profitability after years of market volatility.
🏢 Culture●●●●○
A family-led pharmaceutical firm currently undergoing significant strategic pivots, with the founder-MD heavily involved in turnaround efforts.
Financials
Revenue FY25₹3K Cr
PAT FY25₹-470000000
Rev CAGR 5Y-3.2%
OPM6.2%
NPM-1.6%
ROE-1.1%
ROCE3%
P/E910.8
Fwd P/E—
P/B4.3
D/E50.4
Promoter51%
Institutional14.8%
Mkt Cap₹21K Cr
Compensation
To Be Published
Data being verified from audited reports
